CD274 and non-small cell lung carcinoma: Programmed death-ligand 1 (PD-L1) is currently the only prognostic biomarker recommended by the National Comprehensive Cancer Network for immunotherapy (NCCN), used to formulate treatment strategies for metastatic NSCLC [4].